文献速递哮喘

妊娠期哮喘与急性发作:一项基于人群的队列研究

Pregnancy, asthma and exacerbations: a population-based cohort.
PubMed 文献 · Eur Respir J · 2025-12-18

结果显示妊娠期总发作次数下降约30%,但第二、三孕期因发作住院增加30-45%,产后骤降。31%女性妊娠期减少吸入糖皮质激素使用,此为第二大可干预危险因素。

要点

  • 妊娠期哮喘总发作下降约30%,但住院相关发作在第二、三孕期增加30-45%。
  • 31%妊娠女性减少吸入糖皮质激素使用,使发作风险增加(调整OR 2.29)。
  • 既往发作史是最强危险因素(调整OR 4.09),其他包括血嗜酸性粒细胞增多、吸烟和肥胖。

核心结论

  • 妊娠期总哮喘发作减少,但住院相关发作在第二、三孕期增加,产后骤降。
  • 妊娠期减少吸入糖皮质激素使用是第二大可干预的发作危险因素。

研究设计与样本

  • 采用多变量逻辑回归评估母体特征与发作(主要结局)及吸入糖皮质激素使用(次要结局)的关联。

主要发现

  • 妊娠期总发作次数下降约30%。
  • 住院相关发作在第二和第三孕期增加30-45%,产后骤降。
  • 31%女性妊娠期吸入糖皮质激素处方减少。
  • 发作最强危险因素为既往发作史(调整OR 4.09,95%CI 3.81-4.39)。
  • 妊娠期减少吸入糖皮质激素使用(调整OR 2.29,95%CI 2.12-2.47)和孕前每年≥4次吸入糖皮质激素联合另一种预防药处方(调整OR 2.11,95%CI 1.87-2.37)也是危险因素。

关键数值与推荐

  • 发作定义为短程口服糖皮质激素、急诊就诊或非计划住院。
  • 吸入糖皮质激素减少与孕前哮喘控制欠佳、年龄、种族和吸烟相关。
  • 其他危险因素包括血嗜酸性粒细胞增多、吸烟和肥胖。

临床怎么用

  • 妊娠期应监测哮喘控制并避免减少吸入糖皮质激素使用。
  • 对有既往发作史、血嗜酸性粒细胞增多、吸烟或肥胖的孕妇加强管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Asthma exacerbations during pregnancy are associated with adverse maternal and perinatal outcomes. Identifying modifiable risk factors is essential for improving health outcomes. We aimed to describe exacerbation patterns during pregnancy and identify exacerbation risk factors, particularly modifiable risk factors such as inhaled corticosteroid use. METHODS: This was a cohort study using UK primary care and hospital data (2004-2020) to identify pregnant women with asthma. Exacerbations were defined as a short course of oral corticosteroids, emergency department visit or unscheduled hospital admission. Multivariable logistic regression was used to assess associations between maternal characteristics and exacerbations (primary outcome) and inhaled corticosteroid use (secondary outcome). RESULTS: Among 40 196 pregnant women with asthma, total exacerbations declined by ∼30% during pregnancy. However, exacerbations associated with hospital admission increased by 30-45% during the second and third trimesters, declining abruptly after delivery. Inhaled corticosteroid prescriptions were reduced in 31% of women during pregnancy. Decreased inhaled corticosteroid use was associated with suboptimal asthma control pre-pregnancy, age, ethnicity and smoking. The strongest exacerbation risk factors were a history of exacerbations (adjusted OR 4.09, 95% CI 3.81-4.39), reduced inhaled corticosteroid use during pregnancy (adjusted OR 2.29, 95% CI 2.12-2.47) and ≥4 prescriptions per year for inhaled corticosteroids plus another preventer before pregnancy (adjusted odds ratio 2.11, 95% CI 1.87-2.37). Additional risk factors included blood eosinophilia, smoking and obesity. CONCLUSIONS: Despite fewer total exacerbations, exacerbations associated with a hospital admission increased during pregnancy. One third of women reduced inhaled corticosteroid use during pregnancy, yet this was the second largest exacerbation risk factor and is completely modifiable. Other major risk factors were type 2 inflammation and another modifiable risk factor, suboptimal asthma control pre-pregnancy.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Lee, Wong, Tan, et al. Pregnancy, asthma and exacerbations: a population-based cohort. Eur Respir J. 2025. PMID: 40876965. doi:10.1183/13993003.01327-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。